Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325636 | 0.91 | CREBBP (0.79) | PDE4BTP53MAPTCREBBPKDM4E | |
| SCHEMBL5457658 | 0.88 | PDE4B (0.80) | PDE4BCREBBPKDM4EALDH1A1PKM | |
| SCHEMBL31307824 | 0.86 | MAPT (0.85) | PDE4BTP53MAPTCREBBPKDM4E | |
| SCHEMBL23493909 | 0.86 | MAPT (0.85) | PDE4BTP53MAPTCREBBPKDM4E | |
| SCHEMBL3782313 | 0.86 | MAPT (0.75) | PDE4BTP53MAPTCREBBPKDM4E | |
| SCHEMBL2723613 | 0.85 | CSF1R (0.63) | PDE4BTP53MAPTCREBBPKDM4E | |
| SCHEMBL5468878 | 0.84 | PDE4B (0.75) | PDE4BTP53MAPT | |
| SCHEMBL31307791 | 0.83 | TP53 (0.88) | TP53MAPTCREBBPKDM4EALDH1A1 | |
| SCHEMBL23494146 | 0.83 | TP53 (0.88) | TP53MAPTCREBBPKDM4EALDH1A1 | |
| SCHEMBL8300370 | 0.82 | PDE4B (0.77) | PDE4BTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1673345-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | PDE4B 1/4885TP53 4495/4885MAPT 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.